Use of Biomarkers in Heart Failure

Recommendations for the clinical use of BNP/NT-proBNP and cardiac troponin tests in the clinical management of heart failure

Sponsoring Organization: National Academy of Clinical Biochemistry

Background and Purpose: Although several studies have addressed the use of biomarkers — particularly B-type natriuretic peptide (BNP) and N-terminal pro B-type natriuretic peptide (NT-proBNP) — in populations with heart failure, integrating these markers into clinical care has been controversial. The National Academy of Clinical Biochemistry (NACB) convened a committee to develop practice guidelines for the use of biomarkers for screening, diagnosis, prognostication, and treatment of HF. A separate document focuses on analytical issues pertaining to biomarker measurement.

Key Points:

Normal BNP and NT-proBNP ranges vary according to the assay used and the characteristics of the…

Reviewing Author

Frederick A. Masoudi, MD, MSPH

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)

Frederick A. Masoudi, MD, MSPH

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)